BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26647070)

  • 1. Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies.
    Domin H; Przykaza Ł; Jantas D; Kozniewska E; Boguszewski PM; Śmiałowska M
    Neuropharmacology; 2016 Mar; 102():276-94. PubMed ID: 26647070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effect of the group III mGlu receptor agonist ACPT-I after ischemic stroke in rats with essential hypertension.
    Domin H; Przykaza Ł; Kozniewska E; Boguszewski PM; Śmiałowska M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):93-101. PubMed ID: 29438731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo.
    Domin H; Gołembiowska K; Jantas D; Kamińska K; Zięba B; Smiałowska M
    Neurotox Res; 2014 Jul; 26(1):99-113. PubMed ID: 24402869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid.
    Chapman AG; Talebi A; Yip PK; Meldrum BS
    Eur J Pharmacol; 2001 Jul; 424(2):107-13. PubMed ID: 11476756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of the allosteric agonist of metabotropic glutamate receptor 7 AMN082 on oxygen-glucose deprivation- and kainate-induced neuronal cell death.
    Domin H; Jantas D; Śmiałowska M
    Neurochem Int; 2015 Sep; 88():110-23. PubMed ID: 25576184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats.
    Kłak K; Pałucha A; Brański P; Sowa M; Pilc A
    Amino Acids; 2007 Feb; 32(2):169-72. PubMed ID: 16868652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats.
    Tatarczyńska E; Pałucha A; Szewczyk B; Chojnacka-Wójcik E; Wierońska J; Pilc A
    Pol J Pharmacol; 2002; 54(6):707-10. PubMed ID: 12866729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuroprotective effects of orthosteric agonists of group II and III mGluRs in primary neuronal cell cultures are dependent on developmental stage.
    Jantas D; Gręda A; Gołda S; Korostyński M; Lasoń W
    Neuropharmacology; 2016 Dec; 111():195-211. PubMed ID: 27600687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.
    Pałucha-Poniewiera A; Kłodzińska A; Stachowicz K; Tokarski K; Hess G; Schann S; Frauli M; Neuville P; Pilc A
    Neuropharmacology; 2008 Sep; 55(4):517-24. PubMed ID: 18619473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala.
    Wierońska JM; Szewczyk B; Pałucha A; Brański P; Zieba B; Smiałowska M
    Pharmacol Rep; 2005; 57(6):734-43. PubMed ID: 16382191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling.
    Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A
    Pharmacol Rep; 2006; 58(6):820-6. PubMed ID: 17220539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
    Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K
    Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptide Y Y2 and Y5 receptors as promising targets for neuroprotection in primary neurons exposed to oxygen-glucose deprivation and in transient focal cerebral ischemia in rats.
    Domin H; Przykaza Ł; Jantas D; Kozniewska E; Boguszewski PM; Śmiałowska M
    Neuroscience; 2017 Mar; 344():305-325. PubMed ID: 28057538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.
    Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A
    Neuropharmacology; 2007 Feb; 52(2):306-12. PubMed ID: 17020774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans.
    Uehara S; Muroyama A; Echigo N; Morimoto R; Otsuka M; Yatsushiro S; Moriyama Y
    Diabetes; 2004 Apr; 53(4):998-1006. PubMed ID: 15047615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats.
    Pałucha A; Tatarczyńska E; Brański P; Szewczyk B; Wierońska JM; Kłak K; Chojnacka-Wójcik E; Nowak G; Pilc A
    Neuropharmacology; 2004 Feb; 46(2):151-9. PubMed ID: 14680755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord.
    Howson PA; Jane DE
    Br J Pharmacol; 2003 May; 139(1):147-55. PubMed ID: 12746233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice.
    Pałucha-Poniewiera A; Novák K; Pilc A
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1454-7. PubMed ID: 19660510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
    Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.
    Lopez S; Jouve L; Turle-Lorenzo N; Kerkerian-Legoff L; Salin P; Amalric M
    Neurobiol Dis; 2012 Apr; 46(1):69-77. PubMed ID: 22245662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.